Greenwich LifeSciences, Inc. (GLSI) Stock Analysis & Investment Frameworks
Greenwich LifeSciences, Inc. (GLSI) stock analysis on Invetso. Review Greenwich LifeSciences, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Greenwich LifeSciences, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Greenwich LifeSciences, Inc. Key Financial Metrics
- Market Cap: $215.04M
- Revenue: $N/A
- ROE: -793.76%
- ROIC: -701.55%
- Dividend Yield: N/A
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.